IgGenix Inc, a US-based preclinical antibody discovery and development company, announced on Monday that it has presented data on its lead candidate, IGNX001, an IgG4 monoclonal antibody-based therapeutic for peanut allergy, at the 2024 Annual Conference of the Australasian Society of Clinical Immunology and Allergy (ASCIA) in Adelaide, Australia.
Michael O'Sullivan, MBBS, FRACP, FRCPA, lead investigator, presented information on the company's Phase 1 human clinical trial in peanut allergy. The ACCELERATE Peanut study is active and screening and will assess the safety and tolerability of IGNX001, a therapeutic candidate that is intended to provide the potential for rapid protection for peanut allergic patients.
Derek Croote PhD, IgGenix chief technology officer and co-founder, presented preclinical data on IGNX001, demonstrating robust protection against peanut-mediated mast cell activation, and against anaphylaxis in a murine model of peanut allergy.
The Journal of Allergy and Clinical Immunology has published the complete preclinical findings.
Lilly expands manufacturing footprint in Ireland
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
Merck's GARDASIL 9 shows promise in preventing HPV infection in Japanese males
Pheon Therapeutics names new independent, non-executive director
Solu Therapeutics names new chief medical officer
Tyra Biosciences names new chief medical officer
Arecor reports positive Phase I Results for AT278 insulin at EASD 2024